Evidence map›Paper›PMID 37242988›Full record

ArticleVaccines2023

Long COVID and Hybrid Immunity among Children and Adolescents Post-Delta Variant Infection in Thailand.

Muttharat Jarupan, Watsamon Jantarabenjakul, Peera Jaruampornpan, Jarujan Subchartanan, Chayapa Phasomsap, Taweesak Sritammasiri, Sapphire Cartledge, Pintip Suchartlikitwong, Suvaporn Anugulruengkitt, Surinda Kawichai and 1 more

Abstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Symptoms of long COVID in children and adolescents: a scoping review.Revista da Escola de Enfermagem da U S P · 2025
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Muttharat JarupanDepartment of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Watsamon JantarabenjakulDepartment of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.ORCID 0000-0003-4251-3499
Peera JaruampornpanMonoclonal Antibody Production and Application Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), Pathum Thani 12120, Thailand.
Jarujan SubchartananDepartment of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Chayapa PhasomsapCenter of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand.
Taweesak SritammasiriCenter of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand.
Sapphire CartledgeSchool of Medicine, University of Birmingham, Birmingham B15 2TT, UK.ORCID 0000-0002-5554-1512
Pintip SuchartlikitwongCenter of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand.ORCID 0000-0003-4153-161X
Suvaporn AnugulruengkittDepartment of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.ORCID 0000-0002-6965-5537
Surinda KawichaiCenter of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand.
Thanyawee PuthanakitDepartment of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.ORCID 0000-0003-1873-1867

Funding

Chulalongkorn University RA65/032
6 · The paper itself

Abstract

This study aimed to assess long COVID, and describe immunogenicity against Omicron variants following BNT162b2 vaccination. A prospective cohort study was conducted among children (aged 5-11) and adolescents (aged 12-17) who had SARS-CoV-2 infection from July to December 2021 (Delta predominant period). Long COVID symptoms were assessed by questionnaires at 3 months after infection. Immunogenicity was evaluated by using a surrogate virus-neutralizing antibody test (sVNT) against the Omicron variant. We enrolled 97 children and 57 adolescents. At 3 months, 30 children (31%) and 34 adolescents (60%) reported at least one long COVID symptom, with respiratory symptoms prevailing (25% children and 32% adolescents). The median time from infection to vaccination was 3 months in adolescents and 7 months in children. At 1 month following vaccination, in children who received one-dose and two-dose BNT162b2 vaccines, the median (IQR) sVNT against Omicron was 86.2% inhibition (71.1-91.8) and 79.2% inhibition (61.5-88.9), respectively (

Indexed as

anti-SARS-CoV-2 IgGBNT162b2COVID-19Deltahybrid immunitylong COVID in childrenneutralizing antibody titerOmicronpost COVID-19 conditionsSARS-CoV-2 infection

Identifiers

PMID37242988
PMCPMC10223729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.